Trial Profile

Phase II Study of the Pan-HER Inhibitor Dacomitinib (PF-00299804) for Patients With Locally Advanced or Metastatic Squamous Cell Carcinoma of the Penis.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 May 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 May 2021 Status changed from discontinued to completed.
21 Nov 2020 Status changed from recruiting to discontinued.
16 Sep 2017 According to results published in the BJU International Journal, this study was originally planned according to Simons Optimal two-stage design with the criterion ORR from 5% to a desirable 20% and after achieving positive outcome the trial was amended by introduction of a stronger evidence criterion ORR>20% based on calculation of the Bayesian posterior probability, and a 90% threshold for such a probability was adopted as a stopping rule.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com